<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37170932</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-3083</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of the European Academy of Dermatology and Venereology : JEADV</Title><ISOAbbreviation>J Eur Acad Dermatol Venereol</ISOAbbreviation></Journal><ArticleTitle>Paradoxical joint and muscle pain in a patient treated with anifrolumab and belimumab.</ArticleTitle><Pagination><StartPage>e1198</StartPage><EndPage>e1199</EndPage><MedlinePgn>e1198-e1199</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jdv.19184</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schaeffer</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3132-3542</Identifier><AffiliationInfo><Affiliation>Clinique Dermatologique, H&#xf4;pitaux Universitaires, Strasbourg Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipsker</LastName><ForeName>D</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4675-0336</Identifier><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine, Universit&#xe9; de Strasbourg et Clinique Dermatologique, H&#xf4;pitaux Universitaires, Strasbourg Cedex, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Eur Acad Dermatol Venereol</MedlineTA><NlmUniqueID>9216037</NlmUniqueID><ISSNLinking>0926-9959</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>38RL9AE51Q</RegistryNumber><NameOfSubstance UI="C582345">anifrolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063806" MajorTopicYN="Y">Myalgia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37170932</ArticleId><ArticleId IdType="doi">10.1111/jdv.19184</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Postal M, Vivaldo J, Fernandez-Ruiz R, Paredes J, Appenzeller S, Niewold T. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020;67:87-94.</Citation></Reference><Reference><Citation>Morand E, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211-21.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>